Sulfonic Polymer Complement Modulation for Diabetic Vascular Complications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for preventing and controlling diabetes complications do not effectively target the complement system, leading to significant vascular complications and immune system dysfunction, which contribute to high medical costs and reduced quality of life.
Innovation Solution
A pharmacological composition, including polystyrene sulfonate-based compounds, selectively targets key proteins in the C3 amplification loop of the complement system to inhibit Factor B, Factor D, and Factor H, reducing inflammation and thrombosis, and enhancing immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods for preventing and controlling diabetes complications are used, then current standard care is maintained, but vascular complications occur and immune system function is weakened
Solution Approach 1:
The patent extracts and targets the complement system as a specific harmful pathway within the broader diabetes complication landscape. By identifying and isolating the complement activation loop (C3 amplification loop) as the critical target, the invention removes this specific harmful mechanism from the disease process, leading to reduced inflammation and vascular complications while preserving other immune functions.
Solution Approach 2:
The patent introduces polystyrene sulfonate-based compounds as intermediary substances that selectively interact with the complement system. These compounds act as mediators that bind to and inhibit key complement proteins (Factor B, Factor D, Factor H), thereby blocking the harmful complement activation pathway without directly attacking the immune system or causing widespread immunosuppression.
2Object-affected harmful factors
If the complement system is targeted to reduce inflammation, then vascular complications are reduced, but immune function may be compromised
Solution Approach 1:
The patent applies local quality by selectively targeting only the complement activation loop (C3 amplification loop) rather than suppressing the entire immune system. The polystyrene sulfonate-based compounds specifically inhibit Factor B, Factor D, and Factor H which are localized to the complement pathway, thereby reducing inflammation in vascular tissues while leaving other immune functions intact and unaffected.
Solution Approach 2:
The patent changes the functional parameters of the complement system by introducing polystyrene sulfonate-based compounds that alter the activity state of key complement proteins. These compounds bind to Factor B, Factor D, and Factor H, changing their functional parameters from active to inhibited states, thereby reducing complement-mediated inflammation without globally suppressing immune function.
3Object-affected harmful factors
If comprehensive immune suppression is used to treat diabetes complications, then inflammation is reduced, but immune system function is weakened
Solution Approach 1:
The patent segments the immune system response by focusing exclusively on the complement activation loop (C3 amplification loop) as the target for intervention. This segmentation allows selective inhibition of complement-mediated inflammation and thrombosis pathways while preserving other immune functions. The polystyrene sulfonate-based compounds specifically target Factor B, Factor D, and Factor H, creating a segmented approach that addresses only the harmful complement pathway without suppressing overall immune function.
Data Source
AI summary
Prophylaxis, immune boosting and therapy for vascular complications of diabetes employing various formulations of sulfonic polymers to target and control the activation loop of complement system at C3 level. The molecular targets identified and successfully inhibited are Factor B, Factor D, Factor H. First, this contributes to the inhibition of cross talk pathways in classical and lectin system pathways as well as the C3a and C5a interactions with their receptors. The cross talk pathways inhibit inflammation, oxidative stress, fatty acid synthesis and fibrosis. Secondly, it further inhibits downstream pathways of C5b-9 and also coagulation and thrombotic cascade. Both pathways cause micro vascular and macro vascular complications of diabetes. Thirdly, patient safety is enhanced by Double inhibition of Factor H and Factor D. This reduces adverse effects mediated by individual inhibition of Factor H and Factor D and in addition it has immune boosting effect by targeting immune evasion.